|No phase specified||Biomarker/Laboratory analysis, Natural history/Epidemiology||Active||25 and under||NCI||120178|
- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and young adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to MTC. These problems include adrenal gland tumors, hormone changes, and problems with the bones and other organs. Not much is known about how MTC develops over time, especially in people with MEN2. Researchers want to study MTC in children and young adults and see how it affects their growth and development.
- To study how medullary thyroid cancer affects children and young adults over time.
- Children and young adults younger than 25 years of age who have medullary thyroid cancer.
- Participants will be screened with a brief physical exam and medical history. Blood and tissue samples will be collected to see whether participants have the MEN2 genetic mutation.
- Treatment will not be provided as part of this study. However, participants will be receiving standard care for MTC. They may be eligible for other clinical trials at the National Institutes of Health.
- Participants will have regular study visits every 6 to 12 months to evaluate their MTC and any treatment. Blood tests, imaging studies, and other tests may be performed as needed to monitor the disease.
- Participants and their parents/guardians will also complete questionnaires about their health and emotions during the study.
Further Study Information
- Medullary Thyroid Carcinoma (MTC) is a calcitonin producing tumor arising from the parafollicular C cells of thyroid. In children and young adults, MTC is usually seen in association with Multiple Endocrine Neoplasia (MEN) 2A and 2B, which are rare cancer syndromes resulting from germline mutations of Rearranged during Transfection (RET) proto-oncogene. MTC develops in virtually all patients with MEN 2, and is the leading cause of death in these patients. Patients with MEN 2 may have other characteristic manifestations such as pheochromocytoma and hyperparathyroidism in MEN 2A and pheochromocytoma, ganglioneuromatosis, and skeletal deformities in MEN 2B.
- Complete surgical resection is the only current curative treatment for MTC, and the tumor is unresponsive to standard chemotherapy and conventional doses of radiation therapy. However, more than half the patients present with advanced or metastatic disease and cannot be cured surgically. Novel agents are currently under investigation for treatment of MTC, and vandetanib, an oral RET and receptor tyrosine kinase (RTK) inhibitor was recently approved by the FDA for adults with advanced or metastatic MTC. Vandetanib also has activity in children with hereditary MTC.
- However, complete responses to RTKs have not been observed, and some patients develop resistance to the treatment with RET and RTK inhibitors or have primary refractory disease. The natural history of MTC, particularly in patients with MEN 2, the molecular pathways involved in tumorigenesis, and the development of resistance to targeted therapies are not well understood.
-The overall objective of this longitudinal study is to develop a better understanding of the biology and natural history of MTC, particularly in children and young adults with MEN 2A and 2B, as well as study non-tumor manifestations of MEN 2. This will hopefully allow for developing more effective treatment interventions for tumor and non-tumor related manifestations, and more sensitive endpoints in clinical trials.
- Patients less than or equal to 25 years of age, must have histologically or cytologically confirmed MTC, confirmed by the Laboratory of Pathology, NCI
- Participants may be undergoing standard care or receiving treatment on a clinical trial while participating in this study.
This study will allow for longitudinal evaluations of MTC and non-tumor related manifestations of MEN 2A and 2B in children and young adults. Evaluations will consist of the following (summarized):
1. Clinical and radiological evaluations every 6 12 months
2. Detailed pathologic and molecular analysis of tumor specimens will be performed, including immunohistochemistry (IHC), comparative genomic hybridization (CGH), and genome sequencing.
- INCLUSION CRITERIA:
- Patients must have histologically or cytologically confirmed MTC, confirmed by the Laboratory of Pathology, NCI
- Disease status: Patients must have evidence of active MTC as documented by either elevated plasma biomarkers (CEA and/or calcitonin), or presence of evaluable or measurable disease.
- Age: less than or equal to 25 years of age
- Performance Status: Ability to travel to the NIH and to undergo evaluations to be performed on this protocol.
- Informed Consent: All patients or their legal guardians (if the patients is< 18 years old) must sign an IRB-approved document of informed consent to demonstrate their understanding of the investigational nature and the risks of this study before any protocol-related studies are performed. When appropriate, pediatric subjects will be included in all discussions.
- Prior and current therapy: For the purpose of this study subjects who have not previously received medical or surgical treatment, patients, who have previously received medical or surgical treatment, and subjects who are currently receiving medical treatment and or radiation for a MEN 2 related manifestations will be eligible. Prior and current treatment for MEN 2 related manifestations will be recorded at trial entry and throughout the study.
- Patients must have a primary care provider (for example a primary oncologist or endocrinologist) who can provide and coordinate the medical care for the patient
- In the opinion of the investigator the patient is not able to return for follow-up visits or obtain required follow-up studies.
- Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will not be excluded from participation, but will not undergo radiographic evaluations or other studies for research purposes, which might negatively impact on the pregnancy.
Trial Lead Organizations/Sponsors
National Cancer Institute
|Brigitte C. Widemann||Principal Investigator|
|Claudia P Derse-Anthony||Ph: (301) 402-0199|
|NIH - Warren Grant Magnuson Clinical Center|
|For more information at the NIH Clinical Center contact National Cancer Institute Referral Office||Ph: 888-624-1937|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01660984
ClinicalTrials.gov processed this data on March 16, 2014
Back to Top